Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Single centre, two-way crossover, randomised, open-label study in 20 healthy female
volunteers.The volunteers received an oral single-dose of a combined contraceptive containing
with an oral once daily dose of 1200 mg of BIA 2-093